AUTHOR=Ghebrehiwet Berhane , Jesty Jolyon , Xu Sulan , Vinayagasundaram Rama , Vinayagasundaram Uma , Ji Yan , Valentino Alisa , Hosszu Kinga H., Mathew Sally , Joseph Kusumam , Kaplan Allen P., Peerschke Ellinor I. TITLE=Structure–Function Studies Using Deletion Mutants Identify Domains of gC1qR/p33 as Potential Therapeutic Targets for Vascular Permeability and Inflammation JOURNAL=Frontiers in Immunology VOLUME=2 YEAR=2011 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2011.00058 DOI=10.3389/fimmu.2011.00058 ISSN=1664-3224 ABSTRACT=

The endothelial cell receptor complex for kininogen (HK) comprises gC1qR, cytokeratin 1, and urokinase-type plasminogen activator receptor and is essential for activation of the kinin system that leads to bradykinin (BK) generation. Of these, gC1qR/p33 constitutes a high affinity site for HK – the BK precursor – and is therefore critical for the assembly of the kinin-generating cascade. Previous studies have identified a putative HK site within the C-terminal domain (residues 204–218) of gC1qR recognized by mAb 74.5.2. In these studies, we used information from the crystal structure of gC1qR, to engineer several deletion (Δ) mutants and test their ability to bind and/or support BK generation. While deletion of residues 204–218 (gC1qRΔ204–218), showed significantly reduced binding to HK, BK generation was not affected when tested by a sensitive bradykinin immunoassay. In fact, all of the gC1qR deletion mutants supported BK generation with the exception of gC1qRΔ154–162 and a point mutation in which Trp 233 was substituted with Gly. Binding studies also identified the existence of two additional sites at residues 144–162 and 190–202. Moreover, binding of HK to a synthetic peptide 190–202 was inhibited by mAbs 48 and 83, but not by mAb 74.5.2. Since a single residue separates domains 190–202 and 204–218, they may be part of a highly stable HK binding pocket and therefore a potential target for drug design to prevent vascular permeability and inflammation.